1. Home
  2. CTY vs MGTX Comparison

CTY vs MGTX Comparison

Compare CTY & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTY

City Therapeutics Inc. Common Stock

N/A

Current Price

$17.55

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

N/A

Current Price

$8.37

Market Cap

881.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTY
MGTX
Founded
2023
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
881.7M
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
CTY
MGTX
Price
$17.55
$8.37
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
★ $37.33
$27.75
AVG Volume (30 Days)
250.4K
★ 582.3K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.02
EPS
N/A
★ 0.68
Revenue
N/A
★ $81,391,000.00
Revenue This Year
$62.96
$309.55
Revenue Next Year
$7.47
N/A
P/E Ratio
★ N/A
$12.46
Revenue Growth
N/A
★ 144.57
52 Week Low
$15.81
$6.62
52 Week High
$22.65
$15.35

Technical Indicators

Market Signals
Indicator
CTY
MGTX
Relative Strength Index (RSI) 41.04 36.63
Support Level $16.12 $6.99
Resistance Level $21.98 $10.08
Average True Range (ATR) 2.35 0.52
MACD -0.15 -0.01
Stochastic Oscillator 25.44 6.85

Price Performance

Historical Comparison
CTY
MGTX

About CTY City Therapeutics Inc. Common Stock

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: